HRTX

Heron Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↑ 8/10
  • Value↓ 1/10
Heron Therapeutics sales and earnings growth
HRTX Growth
Good
  • Revenue Y/Y↑ 7.36%
  • EPS Y/Y↓ -33.33%
  • FCF Y/Y↓ -14.88%
Heron Therapeutics gross and profit margin trends
HRTX Profitability
Fair
  • Gross margin ↑ 73.30%
  • EPS margin↓ -13.00%
  • ROIC 5Y↓ -20.96%
Heron Therapeutics net debt vs free cash flow
HRTX Risk
Poor
  • Debt / Equity↑ 9.8
  • Debt / FCF↓ 4.0
  • Interest coverage↓ -1.6

Heron Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

↗ More Biotechnology stocks